Accurate detection of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is critical as therapeutic strategies increasingly emphasize early intervention. While the Mini-Mental State Examination (MMSE) remains a widely used cognitive screening tool, its sensitivity to subtle neurophysiological changes is…
Early and accurate differentiation between Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is increasingly critical as new disease-modifying therapies emphasize intervention at the earliest possible stages. However, MCI often represents a heterogeneous and nonspecific prodromal phase, complicating clinical diagnosis…
ERP Biomarkers of Cognitive Dysfunction in Alzheimer’s Disease: Real-World Evidence Supporting Translational Clinical Trial Endpoints Advances in neuroscience and digital biomarkers are transforming how clinicians and researchers detect, monitor, and study Alzheimer’s disease (AD). At the 2025 Clinical Trials on…